WESLEY OTTO: Open Payments
NPI 1811537483 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,375 in 74 payments from 21 companies in 2025. Trend: 2023 $763 · 2024 $1,096 · 2025 $1,375
Food & beverage: $1,375
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $237 |
| ABBVIE INC. | 15 | $185 |
| Lilly USA, LLC | 9 | $143 |
| Astellas Pharma US Inc | 5 | $113 |
| Novo Nordisk Inc | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $96 |
| Axsome Therapeutics, Inc. | 3 | $90 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Acella Pharmaceuticals, LLC | 2 | $33 |
Products named: AIRSUPRA, MOUNJARO, Veozah, TRINTELLIX, CAPLYTA, FARXIGA, Auvelity, UBRELVY.
Industry payments across TX — which companies pay providers there.
